1. FDA commissioner Dr. Scott Gottlieb said the agency has developed fact sheets and other resources designed to educate healthcare providers about biosimilars and their cost-saving potential. (FDA Voice)
2. Biogen negotiated higher royalties for the future sales of late-stage Alzheimer’s disease drug aducanumab, paying Neurimmune $150 million for a 15% royalty rate reduction. Neurimmune licensed the drug to Biogen in 2007. (BioPharmaDive)
3. GlaxoSmithKline saw a 4% increase in third-quarter sales, driven by demand for its HIV and respiratory drugs. (Reuters)
4. Interpublic Group CEO Michael Roth said its healthcare business, which comprises 22% of the group’s revenue, remained strong despite a 1% overall decrease in third-quarter revenue, to $1.92 billion. (WSJ)
5. Some cancer patients who have limited therapy options are developing their own do-it-yourself experimental therapies. (Gizmodo)
